CODEX ALIMENTARIUS

INTERNATIONAL FOOD STANDARDS



E-mail: codex@fao.org - www.codexalimentarius.org

MAXIMUM RESIDUE LIMITS (MRLs) AND RISK MANAGEMENT RECOMMENDATIONS (RMRs) FOR RESIDUES OF VETERINARY DRUGS IN FOODS

CXM 2-2023

LIST OF ABBREVIATIONS

ADI	Acceptable Daily Intake
ARfD	Acute Reference Dose
BMD	Benchmark Dose
BMDL	Confidence Limit for BMD
bw	Body Weight
CAC	Codex Alimentarius Commission
CCPR	Codex Committee on Pesticide Residues
CCRVDF	Codex Committee on Residues of Veterinary Drugs in Foods
EDI	Estimated Daily Intake
GEADE	Global Estimated Acute Dietary Exposure
GECDE	Global Estimated Chronic Dietary Exposure
JECFA	Joint FAO/WHO Expert Committee on Food Additives
JMPR	Joint FAO/WHO Expert Meeting on Pesticide Residues
LOAEL	Lowest-Observed-Adverse-Effect Level
NOAEL	No-Observed-Adverse-Effect Level
LOQ	Limit of Quantification
mADI	Microbiological Acceptable Daily Intake
MRL	Maximum Residue Limit
RMR	Risk Management Recommendation
TMDI	Theoretical Maximum Daily Intake

Maximum Residue Limits (MRLs)

Abamectin Gentamicin
Albendazole Halquinol
Amoxicillin Imidocarb
Ampicillin Isometamidium
Avylamycin Ivermectin

Azaperone Lasalocid sodium

Benzylpenicillin/Procaine benzylpenicillin Levamisole
Carazolol Lincomycin
Ceftiofur Lufenuron

Chlortetracycline/Oxytetracycline/Tetracycline Melengestrol acetate

Clenbuterol Monensin Closantel Monepantel Colistin Moxidectin Cyfluthrin Narasin Cyhalothrin Neomycin Cypermethrin and alpha-cypermethrin Nicarbazin Danofloxacin Phoxim Deltamethrin Pirlimycin

Derquantel Porcine somatotropin

Dexamethasone Progesterone Diclazuril Ractopamine Dicyclanil Sarafloxacin Diflubenzuron Spectinomycin Dihydrostreptomycin/Streptomycin Spiramycin Diminazene Sulfadimidine Doramectin Teflubenzuron Emamectin benzoate Testosterone **Eprinomectin** Thiabendazole Erythromycin Tilmicosin

Estradiol-17beta Trenbolone acetate
Febantel/Fenbendazole/Oxfendazole Trichlorfon (Metrifonate)

Fluazuron Triclabendazole

Flubendazole Tylosin Flumequine Zeranol

Flumethrin Zilpaterol Hydrochloride

Risk Management Recommendations (RMRs) for Residues of Veterinary Drugs

Carbadox Malachite Green
Chloramphenicol Metronidazole

ChloropromazineNitrofuralDimetridazoleOlaquindoxFurazolidoneRonidazoleGentian VioletStilbens

Ipronidazole

<u>PART I</u>

MAXIMUM RESIDUE LIMITS FOR RESIDUES OF VETERINARY DRUGS IN FOODS

ABAMECTIN (anthelmintic agent)						
JECFA Evalu	ation	45 (1995); 47 ((1996)			
Acceptable D	aily Intake	0-2 μg/kg bw (1997) established for the sum of abamectin and (Z)-8,9 isomer by JMPR (1997)				
Residue Defi	Residue Definition		Avermectin B1a			
Species	Tissue	MRL (µg/kg)	·····- CAC Notes			
Cattle	Liver	100	26 (2003)			
Cattle	Kidney	50 26 (2003)				
Cattle	Fat	100	26 (2003)			

ALBENDAZOLE (anthelmintic agent)				
JECFA Evalua	ation	34 (1989)		
Acceptable Daily Intake		0-50 µg/kg bw	(JECFA34)	
Residue Defin	ition	Except milk, 2-	aminosulfone	e metabolite; Milk, not yet identified
Species	Tissue	MRL (µg/kg)	CAC	Notes
Not specified	Muscle	100	20 (1993)	
Not specified	Liver	5000	20 (1993)	
Not specified	Kidney	5000	20 (1993)	
Not specified	Fat	100 20 (1993)		
Not specified	Milk (µg/l)	100	20 (1993)	

AMOXICILLII	AMOXICILLIN (antimicrobial agent)				
JECFA Evalu	uation	75 (2011); 85 ((2017)		
Microbiologi Daily Intake	cal Acceptable	0–0.002 mg/kg the intestinal m		(bw) based on the effects of amoxicillin on	
Acute Refere	ence Dose	0.005 mg/kg b	w based on n	nicrobiological effects on the intestinal	
Estimated CI Exposure	hronic Dietary	0.14 μg/kg bw of the upper bo		the general population), which represents 7%	
Estimated Ad Exposure	cute Dietary	1.4 μg/kg bw (i microbiologica		al population), which represents 28% of the	
		1.6 µg/kg bw (t ARfD	for children),	which represents 31% of the microbiological	
Residue Defi	inition	Amoxicillin			
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Cattle	Muscle	50	35 (2012)		
Cattle	Liver	50	35 (2012)		
Cattle	Kidney	50	35 (2012)		
Cattle	Fat	50	35 (2012)		
Cattle	Milk	4	35 (2012)		
Sheep	Muscle	50	35 (2012)		
Sheep	Liver	50	35 (2012)		
Sheep	Kidney	50	35 (2012)		
Sheep	Fat	50	35 (2012)		
Sheep	Milk	4	35 (2012)		
Pigs	Muscle	50	35 (2012)		
Pigs	Liver	50	35 (2012)		
Pigs	Kidney	50	35 (2012)		
Pigs	Fat/Skin	50	35 (2012)		
Finfish	Fillet	50	41 (2018)	The term "finfish" includes all fish species Muscle plus skin in natural proportion	
	Muscle	50	41 (2018)	The term "finfish" includes all fish species	

AMPICILLIN (antimicrobial agent)					
JECFA Evaluation 85 (2017)					
Microbiologic Daily Intake	al Acceptable	0–0.003 mg/kg bw based on a NOAEL equivalent to 0.025 mg/kg bw per day for increase in population(s) of ampicillin-resistant bacteria in the gastrointestinal tract in humans, and using a safety factor of 10 (for the variability in the composition of the intestinal microbiota within and between individuals)			
Acute Referei	nce Dose	0.012 mg/kg b	w based on the	e microbiological end-point	
Estimated Ch Exposure	ronic Dietary	0.29 μg/kg bw per day (for the general population), which represents 10% of the upper bound of the ADI			
Estimated Acute Dietary Exposure		1.9 μg/kg bw per day (for the general population), which represents 16% of the ARfD1.7 μg/kg bw per day (for children), which represents 14% of the ARfD			
Residue Defir	nition	Ampicillin			
Note JECFA muscle that rec physica			finfish muscle nded for amoxic al properties a	MRL of 50 µg/kg for ampicillin in finfish plus skin in natural proportion, the same as cillin, because the modes of action, the nd the toxicological and pharmacokinetic picillin are very similar.	
Species	Tissue	MRL (μg/kg) CAC Notes			
Fillet Finfish		50	41 (2018)	The term "finfish" includes all fish species Muscle plus skin in natural proportion	
	Muscle	50	41 (2018)	The term "finfish" includes all fish species	

AVILAMYCIN	۱ (antimicrobial aզ	gent)			
JECFA Evaluation Acceptable Daily Intake		70 (2008)			
		0-2 mg/kg bw on the basis of a NOAEL of 150 mg avilamycin activity/kg bw per day and a safety factor of 100 and rounding to one significant figure (JECFA70)			
Residue Def	inition	Dichloroisoeverr	ninic acid (DI	A)	
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Pigs	Muscle	200	32 (2009)		
Pigs	Liver	300	32 (2009)		
Pigs	Kidney	200	32 (2009)		
Pigs	Fat/Skin	200	32 (2009)		
Chicken	Muscle	200	32 (2009)		
Chicken	Liver	300	32 (2009)		
Chicken	Kidney	200	32 (2009)		
Chicken	Fat/Skin	200	32 (2009)		
Turkey	Muscle	200	32 (2009)		
Turkey	Liver	300	32 (2009)		
Turkey	Kidney	200	32 (2009)		
Turkey	Fat/Skin	200	32 (2009)		
Rabbits	Muscle	200	32 (2009)		
Rabbits	Liver	300	32 (2009)		
Rabbits	Kidney	200	32 (2009)		
Rabbits	Fat/Skin	200	32 (2009)		

AZAPERONE (tranquilizing agent)					
JECFA Evalua	ation	38 (1991); 43 (1	994); 50 (199	08); 52 (1999)	
Acceptable Da	aily Intake	0-6 μg/kg bw (JE	ECFA50)		
Residue Defir	nition	Sum of azaperor	ne and azape	erol	
Species	Tissue	MRL (µg/kg) CAC Notes			
Pig	Muscle	60	23 (1999)		
Pig	Liver	100	23 (1999)		
Pig	Kidney	100 23 (1999)			
Pig	Fat	60	23 (1999)		

BENZYLPEN	BENZYLPENICILLIN/PROCAINE BENZYLPENICILLIN (antimicrobial agent)					
JECFA Evalu	ıation	36 (1990); 50 (1	998)			
Acceptable [Daily Intake			JECFA50). Residues of benzylpenicillin and uld be kept below this level.		
Residue Defi	inition	Benzylpenicillin				
Species	Tissue	MRL (µg/kg)	CAC	Notes		
Cattle	Muscle	50	23 (1999)			
Cattle	Liver	50	23 (1999)			
Cattle	Kidney	50	23 (1999)			
Cattle	Milk (µg/l)	4	23 (1999)			
Chicken	Muscle	50	23 (1999)	Applies to procaine benzylpenicillin only		
Chicken	Liver	50	23 (1999)	Applies to procaine benzylpenicillin only		
Chicken	Kidney	50	23 (1999)	Applies to procaine benzylpenicillin only		
Pig	Muscle	50	23 (1999)			
Pig	Liver	50	23 (1999)			
Pig	Kidney	50	23 (1999)			

CARAZOLOL	CARAZOLOL (beta-adreniceptor-blocking agent)						
JECFA Evalu	ation	38 (1991); 43 (1	994); 52 (199	99)			
Acceptable D	aily Intake		0-0.1 μg/kg bw (JECFA43). ADI based on the acute pharmacological effects of carazolol				
Residue Defin	nition	Carazolol					
Species	Tissue	MRL (μg/kg) CAC Notes					
Pig	Muscle	5	26 (2003)	The concentration at the injection site two hours after treatment may result in an intake that exceeds the ARfD and therefore, an appropriate withdrawal period should be applied			
Pig	Liver	25	26 (2003)				
Pig	Kidney	25	26 (2003)				
Pig	Fat/Skin	5	26 (2003)	The concentration at the injection site two hours after treatment may result in an intake that exceeds the ARfD and therefore, an appropriate withdrawal period should be applied			

CEFTIOFUR (antimicrobial agent)				
JECFA Evalu	ation	45 (1995); 48 (1	997)	
Acceptable D	aily Intake	0-50 μg/kg bw (JECFA45)	
Residue Defii	nition	Desfuroylceftiofu	ır	
Species	Tissue	MRL (µg/kg)	CAC	Notes
Cattle	Muscle	1000	23 (1999)	
Cattle	Liver	2000	23 (1999)	
Cattle	Kidney	6000	23 (1999)	
Cattle	Fat	2000	23 (1999)	
Cattle	Milk (µg/l)	100	23 (1999)	
Pig	Muscle	1000	23 (1999)	
Pig	Liver	2000	23 (1999)	
Pig	Kidney	6000	23 (1999)	
Pig	Fat	2000	23 (1999)	

JECFA Evaluation Acceptable Daily Intake		45 (1995); 47 (1	45 (1995); 47 (1996); 50 (1998); 58 (2002) Group ADI for chlortetracycline, oxytetracycline and tetracycline: 0-30 μg/kg bw (JECFA50). Group ADI for chlortetracycline, oxytetracycline and tetracycline.			
		0-30 µg/kg bw (
Residue Defi	nition	Parent drugs, si	ngly or in cor	nbination		
Species	Tissue	MRL (µg/kg)	CAC	Notes		
Cattle	Muscle	200	26 (2003)			
Cattle	Liver	600	26 (2003)			
Cattle	Kidney	1200	26 (2003)			
Cattle	Milk (µg/l)	100	26 (2003)			
Fish	Muscle	200	26 (2003)	Applies only to oxytetracycline		
Giant prawn (Paeneus monodon)	Muscle	200	26 (2003)	Applies only to oxytetracycline		
Pig	Muscle	200	26 (2003)			
Pig	Liver	600	26 (2003)			
Pig	Kidney	1200	26 (2003)			
Poultry	Muscle	200	26 (2003)			
Poultry	Liver	600	26 (2003)			
Poultry	Kidney	1200	26 (2003)			
Poultry	Eggs	400	26 (2003)			
Sheep	Muscle	200	26 (2003)			
Sheep	Liver	600	26 (2003)			
Sheep	Kidney	1200	26 (2003)			
Sheep	Milk (µg/l)	100	26 (2003)			

CLENBUTER	OL (adrenocepto	r agonist)				
JECFA Evalu	ation	47 (1996)				
Acceptable D	aily Intake	0-0.004 μg/kg b	w (JECFA47))		
Residue Defi	nition	Clenbuterol				
Species	Tissue	MRL (µg/kg)	CAC	Notes		
Cattle	Muscle	0.2	26 (2003)	Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases		
Cattle	Liver	0.6	26 (2003)	Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases		
Cattle	Kidney	0.6	26 (2003)	Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases		
Cattle	Fat	0.2	26 (2003)	Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases		
Cattle	Milk (μg/l)	0.05	26 (2003)	Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases		
Horse	Muscle	0.2	26 (2003)	Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases		
Horse	Liver	0.6	26 (2003)	Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases		
Horse	Kidney	0.6	26 (2003)	Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases		
Horse	Fat	0.2	26 (2003)	Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases		

CLOSANTEL (anthelmintic agent)					
JECFA Evalu	ation	36 (1990); 40 ((1992)		
Acceptable D	aily Intake	0-30 µg/kg bw	(JECFA40)		
Residue Defi	nition	Closantel			
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Cattle	Muscle	1000	20 (1993)		
Cattle	Liver	1000	20 (1993)		
Cattle	Kidney	3000	20 (1993)		
Cattle	Fat	3000	20 (1993)		
Sheep	Muscle	1500	20 (1993)		
Sheep	Liver	1500	20 (1993)		
Sheep	Kidney	5000	20 (1993)		
Sheep	Fat	2000	20 (1993)		

COLISTIN (antimicrobial agent)							
JECFA Evalu	ation	66 (2006)	66 (2006)				
Acceptable D	aily Intake	0-7 μg/kg bw (JECFA66)					
Residue Defi	nition	Sum of colistin A	and colistin	В			
Species	Tissue	MRL (µg/kg)	CAC	Notes			
Cattle	Muscle	150	31 (2008)				
Cattle	Liver	150	31 (2008)				
Cattle	Kidney	200	31 (2008)				
Cattle	Fat	150	31 (2008)				
Cattle	Milk	50	31 (2008)				
Sheep	Muscle	150	31 (2008)				
Sheep	Liver	150	31 (2008)				
Sheep	Kidney	200	31 (2008)				
Sheep	Fat	150	31 (2008)				
Sheep	Milk	50	31 (2008)				
Goat	Muscle	150	31 (2008)				
Goat	Liver	150	31 (2008)				
Goat	Kidney	200	31 (2008)				
Goat	Fat	150	31 (2008)				
Pig	Muscle	150	31 (2008)				
Pig	Liver	150	31 (2008)				
Pig	Kidney	200	31 (2008)				
Pig	Fat	150	31 (2008)	The MRL includes skin + fat			
Chicken	Muscle	150	31 (2008)				
Chicken	Liver	150	31 (2008)				
Chicken	Kidney	200	31 (2008)				
Chicken	Fat	150	31 (2008)	The MRL includes skin + fat			
Chicken	Eggs	300	31 (2008)				
Turkey	Muscle	150	31 (2008)				
Turkey	Liver	150	31 (2008)				
Turkey	Kidney	200	31 (2008)				
Turkey	Fat	150	31 (2008)	The MRL includes skin + fat			
Rabbit	Muscle	150	31 (2008)				
Rabbit	Liver	150	31 (2008)				
Rabbit	Kidney	200	31 (2008)				
Rabbit	Fat	150	31 (2008)				

CYFLUTHRIN (insecticide)					
JECFA Evalu	ation	48 (1997)			
Acceptable D	aily Intake	0-20 μg/kg bw	(JECFA48)		
Residue Defi	nition	Cyfluthrin			
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Cattle	Muscle	20	26 (2003)		
Cattle	Liver	20	26 (2003)		
Cattle	Kidney	20	26 (2003)		
Cattle	Fat	200 26 (2003)			
Cattle	Milk (µg/l)	40	26 (2003)		

CYHALOTHR	CYHALOTHRIN (insecticide)						
JECFA Evaluation		54 (2000); 58 (2	54 (2000); 58 (2002); 62 (2004)				
Acceptable D	aily Intake	0-5 μg/kg bw (JE	ECFA62)				
Residue Defir	nition	Cyhalothrin					
Species	Tissue	MRL (µg/kg)	CAC	Notes			
Cattle	Muscle	20	28 (2005)				
Cattle	Liver	20	28 (2005)				
Cattle	Kidney	20	28 (2005)				
Cattle	Fat	400	28 (2005)				
Cattle	Milk	30	28 (2005)				
Pig	Muscle	20	28 (2005)				
Pig	Liver	20	28 (2005)				
Pig	Kidney	20	28 (2005)				
Pig	Fat	400	28 (2005)				
Sheep	Muscle	20	28 (2005)				
Sheep	Liver	50	28 (2005)				
Sheep	Kidney	20	28 (2005)				
Sheep	Fat	400	28 (2005)				

CYPERMETHRIN AND ALPHA-CYPERMETHRIN (insecticide)					
JECFA Evaluation 62 (2004)		62 (2004)			
Acceptable D	aily Intake	JECFA62 establi		non ADI of 0-20 μg/kg bw for both methrin	
Residue Defi	nition	Total of cyperme alpha-cypermeth		s (resulting from the use of cypermethrin or ary drugs)	
Species	Tissue	MRL (µg/kg) CAC Note			
Cattle	Muscle	50	29 (2006)		
Cattle	Liver	50	29 (2006)		
Cattle	Kidney	50	29 (2006)		
Cattle	Fat	1000	29 (2006)		
Cattle	Milk	100	29 (2006)		
Sheep	Muscle	50 29 (2006)			
Sheep	Liver	50 29 (2006)			
Sheep	Kidney	50 29 (2006)			
Sheep	Fat	1000	29 (2006)		

DANOFLOXACIN (antimicrobial agent)							
JECFA Evalu	JECFA Evaluation		48 (1997)				
Acceptable D	Daily Intake	0-20 μg/kg bw	(JECFA48)				
Residue Defi	nition	Danofloxacin					
Species	Tissue	MRL (µg/kg)	CAC	Notes			
Cattle	Muscle	200	24 (2001)				
Cattle	Liver	400	24 (2001)				
Cattle	Kidney	400	24 (2001)				
Cattle	Fat	100	24 (2001)				
Chicken	Muscle	200	24 (2001)				
Chicken	Liver	400	24 (2001)				
Chicken	Kidney	400	24 (2001)				
Chicken	Fat	100	24 (2001)	Fat/skin in normal proportion			
Pig	Muscle	100	24 (2001)				
Pig	Liver	50	24 (2001)				
Pig	Kidney	200	24 (2001)				
Pig	Fat	100	24 (2001)				

DELTAMETHRIN (insecticide)							
JECFA Evalu	JECFA Evaluation		52 (1999); 60 (2003)				
Acceptable I	Daily Intake	0-10 μg/kg bw	(1982). Esta	blished by JMPR (1982).			
Residue Def	inition	Deltamethrin					
Species	Tissue	MRL (µg/kg)	CAC	Notes			
Cattle	Muscle	30	26 (2003)				
Cattle	Liver	50	26 (2003)				
Cattle	Kidney	50	26 (2003)				
Cattle	Fat	500	26 (2003)				
Cattle	Milk	30	26 (2003)				
Chicken	Muscle	30	26 (2003)				
Chicken	Liver	50	26 (2003)				
Chicken	Kidney	50	26 (2003)				
Chicken	Fat	500	26 (2003)				
Chicken	Eggs	30	26 (2003)				
Salmon	Muscle	30	26 (2003)				
Sheep	Muscle	30	26 (2003)				
Sheep	Liver	50	26 (2003)				
Sheep	Kidney	50	26 (2003)				
Sheep	Fat	500	26 (2003)				

DERQUANTEL (anthelmintic agent)					
JECFA Evalua	ation	75 (2011); 78 ((2013)		
a		0-0.3 µg/kg bw on the basis of a LOAEL of 0.1 mg/kg bw per day for acute clinical observations in dogs, consistent with antagonistic activity on the nicotinic acetylcholine receptors. A safety factor of 300 was applied to the LOAEL. (JECFA75)			
Estimated Die	etary Exposure	There were insufficient data to calculate an EDI, and the TMDI approach was used. Using the model diet and the MT:TR approach, these MRLs result in an estimated dietary exposure of 6.8 µg/person, which represents approximately 38% of the upper bound of the ADI. (JECFA78)		diet and the MT:TR approach, these MRLs / exposure of 6.8 µg/person, which	
Residue Defir	nition	Derquantel			
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Sheep	Muscle	0.3 38 (2015)			
Sheep	Liver	0.8 38 (2015)			
Sheep	Kidney	0.4 38 (2015)			
Sheep	Fat	7.0	38 (2015)		

DEXAMETHASONE (glucocorticosteroid)						
JECFA Evaluation		70 (2008)	70 (2008)			
Acceptable D	aily Intake	0-0.015 μg/kg	bw (JECFA42	2)		
Residue Defi	nition	Dexamethasor	ne			
Species	Tissue	MRL (µg/kg)	······································			
Cattle	Muscle	1.0	32 (2009)			
Cattle	Liver	2.0	32 (2009)			
Cattle	Kidney	1.0	32 (2009)			
Cattle	Milk (µg/l)	0.3	32 (2009)			
Pig	Muscle	1.0	32 (2009)			
Pig	Liver	2.0	32 (2009)			
Pig	Kidney	1.0	32 (2009)			
Horses	Muscle	1.0	32 (2009)			
Horses	Liver	2.0	32 (2009)			
Horses	Kidney	1.0	32 (2009)			

DICLAZURIL	DICLAZURIL (antiprotozoal agent)					
JECFA Evaluation		45 (1995); 50 (45 (1995); 50 (1998)			
Acceptable D	aily Intake	0-30 µg/kg bw	(JECFA50)			
Residue Defir	nition	Diclazuril				
Species	Tissue	MRL (µg/kg)	CAC	Notes		
Poultry	Muscle	500	23 (1999)			
Poultry	Liver	3000	23 (1999)			
Poultry	Kidney	2000	23 (1999)			
Poultry	Fat/Skin	1000	23 (1999)			
Rabbit	Muscle	500	23 (1999)			
Rabbit	Liver	3000	23 (1999)			
Rabbit	Kidney	2000	23 (1999)			
Rabbit	Fat	1000	23 (1999)			
Sheep	Muscle	500	23 (1999)			
Sheep	Liver	3000	23 (1999)			
Sheep	Kidney	2000	23 (1999)			
Sheep	Fat	1000	23 (1999)			

DICYCLANIL (insecticide)				
JECFA Evalua	ation	54 (2000); 60 (2003)	
Acceptable D	aily Intake	0-7 μg/kg bw (JECFA54)	
Residue Defir	nition	Dicyclanil		
Species	Tissue	MRL (µg/kg)	CAC	Notes
Sheep	Muscle	150	28 (2005)	
Sheep	Liver	125	28 (2005)	
Sheep	Kidney	125 28 (2005)		
Sheep	Fat	200	28 (2005)	

DIFLUBENZURON (insecticide)

JECFA Evalu	ation	88 (2019)			
Acceptable d	aily intake	JECFA established an ADI of 0–0.02 mg/kg bw – based on a NOAEL of 2 mg/kg bw per day for increased methaemoglobin and sulfhaemoglobin levels in a 2-year study of toxicity and carcinogenicity in rats; and increased methaemoglobin and sulfhaemoglobin levels, platelet counts and hepatic pigmentation in a 1-year study of toxicity in dogs – applying a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability).			
Acute reference dose		JECFA reiterated the conclusion of the 81st meeting (1) that it was not necessary to establish an ARfD, in view of the low acute oral toxicity and the absence of developmental toxicity, and any other toxicological effects likely to be elicited by a single dose.			
Estimated chronic dietary exposure		The GECDE for the general population is 0.84 µg/kg bw per day, which represents 4% of the upper bound of the ADI. The GECDE for children is 2.85 µg/kg bw per day, which represents 14% of the upper bound of the ADI.			
Estimated ac exposure	ute dietary	The acute dietary exposure was not estimated because JECFA concluded that it was not necessary to establish an ARfD.			
Residue definition		JECFA reconfirmed Diflubenzuron as the marker residue (MR) and the ratio of the MR to the total radioactive residue (TRR) of 0.9 established at its 81st meeting.			
Maximum residue limits		JECFA recommended an MRL in salmon of 10 μg/kg in muscle plus skin in natural proportions.			
Species	Tissue	MRL (μg/kg) CAC Notes			
Salmon	Muscle plus skin in natural proportions	10	44 (2021)		

JECFA Evaluation Acceptable Daily Intake		43 (1994); 48	43 (1994); 48 (1997); 52 (1999); 58 (2002) 0-50 μg/kg bw (JECFA48). Group ADI for combined residues of dihydrostreptomycin and streptomycin.			
Residue Def	finition	Sum of dihydro	ostreptomycir	n and streptomycin		
Species	Tissue	MRL (µg/kg)	CAC	Notes		
Cattle	Muscle	600	24 (2001)			
Cattle	Liver	600	24 (2001)			
Cattle	Kidney	1000	24 (2001)			
Cattle	Fat	600	24 (2001)			
Cattle	Milk	200	26 (2003)			
Chicken	Muscle	600	24 (2001)			
Chicken	Liver	600	24 (2001)			
Chicken	Kidney	1000	24 (2001)			
Chicken	Fat	600	24 (2001)			
Pig	Muscle	600	24 (2001)			
Pig	Liver	600	24 (2001)			
Pig	Kidney	1000	24 (2001)			
Pig	Fat	600	24 (2001)			
Sheep	Muscle	600	24 (2001)			
Sheep	Liver	600	24 (2001)			
Sheep	Kidney	1000	24 (2001)			
Sheep	Fat	600	24 (2001)			
Sheep	Milk	200	26 (2003)			

DIMINAZENE (trypanocide)				
JECFA Evalua	ation	34 (1989); 42 (1994)		
Acceptable D	aily Intake	0-100 μg/kg bv	v (JECFA42)	
Residue Defir	nition	Diminazene		
Species	Tissue	MRL (μg/kg) CAC Notes		Notes
Cattle	Muscle	500	22 (1997)	
Cattle	Liver	12000 22 (1997)		
Cattle	Kidney	6000 22 (1997)		
Cattle	Milk (µg/l)	150	22 (1997)	LOQ of the analytical method

DORAMECT	IN (anthelmintic a	gent)						
JECFA Evalu	uation	45 (1995); 52 (1	45 (1995); 52 (1999); 58 (2002); 62 (2004)					
Acceptable [Daily Intake	0-1 μg/kg bw (Jl	0-1 μg/kg bw (JECFA58)					
Residue Defi	inition	Doramectin						
Species	Tissue	MRL (µg/kg)	CAC	Notes				
Cattle	Muscle	10	22 (1997)	High concentration of residues at the injection site over a 35 day period after subcutaneous or intramuscular administration of the drug at the recommended dose				
Cattle	Liver	100	22 (1997)					
Cattle	Kidney	30	22 (1997)					
Cattle	Fat	150	22 (1997)	High concentration of residues at the injection site over a 35 day period after subcutaneous or intramuscular administration of the drug at the recommended dose				
Cattle	Milk	15	29 (2006)	Depending on the route and/or time of administration the use of doramectin in dairy cows may result in extended withdrawal periods in milk. This may be addressed in national/regional regulatory programmes.				
Pig	Muscle	5	24 (2001)					
Pig	Liver	100	24 (2001)					
Pig	Kidney	30	24 (2001)					
Pig	Fat	150	24 (2001)					

EMAMECTIN	EMAMECTIN BENZOATE (antiparasitic agent)				
JECFA Evaluation 78 (2013)					
ACCEPTABLE Daily Intake ADI of 0–0.5 µg/kg bw established by JMPR (2011), based on a NOAEL of 0.25 mg/kg bw per day for neurotoxicity from 14- and week studies in dogs, supported by an overall NOAEL of 0.25 m per day from 1- and 2-year studies in rats. An uncertainty factor was applied to the NOAEL, which includes an additional uncerta factor of 5 to account for the steep dose–response curve and in histopathological effects in neural tissues at the lowest-observe adverse-effect level (LOAEL) in dogs, as used by JMPR and co by JECFA78.			day for neurotoxicity from 14- and 53- ed by an overall NOAEL of 0.25 mg/kg bw dies in rats. An uncertainty factor of 500 ich includes an additional uncertainty eep dose–response curve and irreversible tral tissues at the lowest-observed-		
Estimated Die	etary Exposure	11 μg/person per day, which represents approximately 37% of the upper bound of the ADI (JECFA78)			
Residue Defin	nition	Emamectin B1a			
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Salmon Muscle		100	38 (2015)		
Salmon	Fillet	100 38 (2015) Muscle plus skin in natural proportion			
Trout	Muscle	100	38 (2015)		
Trout	Fillet	100	38 (2015)	Muscle plus skin in natural proportion	

EPRINOMECTIN (anthelmintic agent)						
JECFA Evalua	ation	50 (1998)				
Acceptable D	Acceptable Daily Intake		0-10 μg/kg bw (JECFA50)			
Residue Defin	Eprinomectin B1a					
Species	Tissue	MRL (μg/kg) CAC Notes				
Cattle	Muscle	100	26 (2003)			
Cattle	Liver	2000 26 (2003)				
Cattle	Kidney	300 26 (2003)				
Cattle	Fat	250 26 (2003)				
Cattle	Milk (µg/l)	20	26 (2003)			

ERYTHROMY	ERYTHROMYCIN (antimicrobial agent)					
JECFA Evalua	ation	66 (2006)				
Acceptable Da	aily Intake	0-0.7 μg/kg bw (JECFA66)			
Residue Defin	nition	Erythromycin A				
Species	Tissue	MRL (μg/kg) CAC Notes				
Chicken	Muscle	100	31 (2008)			
Chicken	Liver	100	31 (2008)			
Chicken	Kidney	100	31 (2008)			
Chicken	Fat	100	31 (2008)	The MRL includes skin + fat		
Chicken	Eggs	50	31 (2008)			
Turkey	Muscle	100	31 (2008)			
Turkey	Liver	100	31 (2008)			
Turkey	Kidney	100	31 (2008)			
Turkey	Fat	100	31 (2008)	The MRL includes skin + fat		

ESTRADIOL	-17BETA (produc	ction aid)					
JECFA Eval	uation	25 (1981); 32 (25 (1981); 32 (1987); 52 (1999)				
Acceptable	Daily Intake	unnecessary (J	IECFA32); 0-	0.05 μg/kg bw (JECFA52)			
Residue Def	inition	Estradiol-17bet	a.				
Species	Tissue	MRL (µg/kg)	CAC	Notes			
Cattle	Muscle	unnecessary	21 (1995)	Residues resulting from the use of this substance as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health			
Cattle	Liver	unnecessary	21 (1995)	Residues resulting from the use of this substance as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health			
Cattle	Kidney	unnecessary	21 (1995)	Residues resulting from the use of this substance as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health			
Cattle	Fat	unnecessary	21 (1995)	Residues resulting from the use of this substance as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health			

FEBANTEL/FENBENDAZOLE/OXFENDAZOLE (anthelmintic agent)							
JECFA Evalu	ation	38 (1991); 45 (1995); 50 (1998)					
Acceptable D	Acceptable Daily Intake		Group ADI of 0-7 μg/kg bw (JECFA50)				
Residue Defi	nition			ndazole and oxfendazole sulphone, sulphone equivalents			
Species	Tissue	MRL (µg/kg)	I ('A(' I NOTOS				
Cattle	Muscle	100	23 (1999)				
Cattle	Liver	500	23 (1999)				
Cattle	Kidney	100	23 (1999)				
Cattle	Fat	100	23 (1999)				
Cattle	Milk (µg/l)	100	23 (1999)				
Goat	Muscle	100	23 (1999)				
Goat	Liver	500	23 (1999)				
Goat	Kidney	100	23 (1999)				
Goat	Fat	100	23 (1999)				
Horse	Muscle	100	23 (1999)				
Horse	Liver	500	23 (1999)				
Horse	Kidney	100	23 (1999)				
Horse	Fat	100	23 (1999)				
Pig	Muscle	100	23 (1999)				
Pig	Liver	500	23 (1999)				
Pig	Kidney	100	23 (1999)				
Pig	Fat	100	23 (1999)				
Sheep	Muscle	100	23 (1999)				
Sheep	Liver	500	23 (1999)				
Sheep	Kidney	100	23 (1999)				
Sheep	Fat	100	23 (1999)				
Sheep	Milk (µg/l)	100	23 (1999)				

FLUAZURON (insecticide)				
JECFA Evalua	ation	48 (1997)		
Acceptable D	Acceptable Daily Intake		(JECFA48)	
Residue Defir	nition	Fluazuron		
Species	Tissue	MRL (μg/kg) CAC Notes		
Cattle	Muscle	200	23 (1999)	
Cattle	Liver	500 23 (1999)		
Cattle	Kidney	500 23 (1999)		
Cattle	Fat	7000	23 (1999)	

FLUBENDAZOLE (anthelmintic agent)					
JECFA Evalu	ation	40 (1992)			
Acceptable Daily Intake		0-12 μg/kg bw	(JECFA40)		
Residue Defi	nition	Flubendazole			
Species	Tissue	MRL (μg/kg) CAC Notes			
Pig	Muscle	10	21 (1995)		
Pig	Liver	10	21 (1995)		
Poultry	Muscle	200 21 (1995)			
Poultry	Liver	500 21 (1995)			
Poultry	Eggs	400	21 (1995)		

FLUMEQUIN	E (antimicrobial a	gent)					
JECFA Evalu	uation	42 (1994); 48 (42 (1994); 48 (1997); 54 (2000); 60 (2002); 62 (2004); 66 (2006)				
Acceptable [Daily Intake	0-30 μg/kg bw	(JECFA62)				
Residue Defi	inition	Flumequine					
Species	Tissue	MRL (µg/kg)	CAC	Notes			
Cattle	Muscle	500	28 (2005)				
Cattle	Liver	500	28 (2005)				
Cattle	Kidney	3000	28 (2005)				
Cattle	Fat	1000	28 (2005)				
Chicken	Muscle	500	28 (2005)				
Chicken	Liver	500	28 (2005)				
Chicken	Kidney	3000	28 (2005)				
Chicken	Fat	1000	28 (2005)				
Pig	Muscle	500	28 (2005)				
Pig	Liver	500	28 (2005)				
Pig	Kidney	3000	28 (2005)				
Pig	Fat	1000	28 (2005)				
Sheep	Muscle	500	28 (2005)				
Sheep	Liver	500	28 (2005)				
Sheep	Kidney	3000	28 (2005)				
Sheep	Fat	1000	28 (2005)				
Trout	Muscle	500	28 (2005)	Muscle including normal proportion of skin			

FLUMETHRIN (insecticide)

JECFA Evaluation	n	85 (2017)			
Acceptable Daily	Intake	0–0.004 mg/kg bw based on the NOAEL of 0.37 mg/kg bw per day for skin lesions in parental animals and reduced survival and body weight gain in pups in a two-generation toxicity study in rats and using a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability).			
Acute Reference	dose	0.005 mg/kg bw based on the NOAEL of 0.5 mg/kg bw for salivation in dams in a developmental toxicity study in rats and using a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability).			
Estimated chron	ic dietary exposure	 0.008 μg/kg bw per day (for the general population), which represents 0.2% of the upper bound of the ADI. 0.006 μg/kg bw per day (for children), which represents 0.2% of the upper bound of the ADI. 			
		Note: As Flumethrin is also used as pesticide the overall dietary exposure was estimated. The assumptions and detailed results will be displayed in the JECFA85 report. Results below are only for use as veterinary drug.			
Estimated Acute	Dietary Exposure	 0.1 μg/kg bw per day (for the general population), which represents 2.2% of the ARfD. 0.1 μg/kg bw per day (for children), which represents 2.2% of the ARfD. 			
Residue Definition	on	Flumethrin (trans-Z1 and trans Z2 diastereomers at a ratio of approximately 60:40).			
Species	Tissue	MRL (µg/kg)	CAC	Note	
	Honey	Unnecessary	CAC44 (2021)	Residues resulting from the use of this substances as an insecticide in accordance with good practice for veterinary drug are unlikely to pose a hazard to human health.	

GENTAMICIN (antimicrobial agent)				
JECFA Evalu	ation	43 (1994); 48 ((1997); 50 (19	998)
Acceptable D	aily Intake	0-20 μg/kg bw	(JECFA50)	
Residue Defin	nition	Gentamicin		
Species	Tissue	MRL (µg/kg)	CAC	Notes
Cattle	Muscle	100	24 (2001)	
Cattle	Liver	2000	24 (2001)	
Cattle	Kidney	5000	24 (2001)	
Cattle	Fat	100	24 (2001)	
Cattle	Milk (µg/l)	200	24 (2001)	
Pig	Muscle	100	24 (2001)	
Pig	Liver	2000	24 (2001)	
Pig	Kidney	5000	24 (2001)	
Pig	Fat	100	24 (2001)	

HALQUINOL (broad-spectrum antimicrobial)

JECFA Evalu	ıation	88 (2019)				
Acceptable o	laily intake	histopathologic absolute and re rats, applying a	JECFA established an ADI of 0–0.2 mg/kg bw, based on histopathological changes in the kidney, accompanied by increases in absolute and relative renal weight in a 1-year chronic toxicity study in rats, applying a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability).			
Acute referen	nce dose	JECFA established an ARfD of 0.3 mg/kg bw, based on a NOAEL of 30 mg/kg bw for clinical signs in dams observed in a developmental toxicity study in mice, with application of a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability).				
Estimated chexposure	ronic dietary			population is 5.9 μg/kg bw per day, which bound of the ADI.		
		The GECDE for of the upper bo		6.9 μg/kg bw per day, which represents 3.4% DI.		
Estimated acute dietary exposure The GEADE was comparable for children 224 µg/kg bw per day, which represents 0						
Residue defi	nition	The marker residue (MR) is the sum of 5-chloroquinolin-8-ol (5-CL), 5,7-dichloroquinolin-8-ol 5,7-DCL (5,7-DCL) and their glucuronide metabolites: 5-CLG (expressed as 5-CL equivalents) and 5,7-DCLG (expressed as 5,7-DCL equivalents).				
Maximum res	sidue limits	JECFA recommended MRLs in swine of 40 μg/kg for muscle, 350 μg/kg for skin plus fat, 500 μg/kg for liver and 9000 μg/kg for kidney.				
Species	Tissue	MRL (μg/kg) CAC Notes				
Swine	Muscle	40	44 (2021)			
Swine	Skin plus fat	350	44 (2021)			
Swine	Liver	500	44 (2021)			
Swine	Kidney	9000	44 (2021)			

IMIDOCARB (antiprotozoal agent)				
JECFA Evalua	ation	50 (1998); 60 ((2003)	
Acceptable Daily Intake		0-10 µg/kg bw	(JECFA50)	
Residue Defin	nition	Imidocarb		
Species	Tissue	MRL (µg/kg)	CAC	Notes
Cattle	Muscle	300	28 (2005)	
Cattle	Liver	1500	28 (2005)	
Cattle	Kidney	2000	28 (2005)	
Cattle	Fat	50	28 (2005)	
Cattle	Milk	50	28 (2005)	

ISOMETAMIDIUM (trypanocide)				
JECFA Evalua	ation	34 (1989); 40 ((1992)	
Acceptable D	aily Intake	0-100 μg/kg by	v (JECFA40)	
Residue Defir	nition	Isometamidiun	า	
Species	Tissue	MRL (µg/kg)	CAC	Notes
Cattle	Muscle	100	21 (1995)	
Cattle	Liver	500	21 (1995)	
Cattle	Kidney	1000	21 (1995)	
Cattle	Fat	100 21 (1995)		
Cattle	Milk (µg/l)	100	21 (1995)	

IVERMECTIN	IVERMECTIN (broad-spectrum antiparasitic agent)				
JECFA Evaluation		36 (1990); 40 (1992); 54 (2000); 58 (2002); 81 (2015); 94 (2021)			
Acceptable Daily Intake		0–10 μg/kg bo	dy weight (JE	CFA81)	
Acute Refere	nce Dose	200 μg/kg bod	y weight (JEC	CFA81)	
Estimated Acute Dietary Exposure		The GEADE for cattle muscle, applicable to children and the general population, is 69 µg/kg bw, which represents 35% of the ARfD of 200 µg/kg bw. The GEADE for sheep muscle, applicable to children and the general population, is 73 µg/kg bw, which represents 37% of the ARfD of 200 µg/kg bw. The GEADE for pig muscle, applicable to children and the general population, is 30 µg/kg bw, which represents 15% of the ARfD of 200 µg/kg bw. (JECFA94)			
Estimated Ch Exposure	nronic Dietary	The GECDE for adults and the elderly is 0.72 μg/kg bw per day, which represents 7.2% of the upper bound of the ADI of 10 μg/kg bw. The GECDE for children and adolescents is 0.93 μg/kg bw per day, which represents 9.3% of the upper bound of the ADI of 10 μg/kg bw. The GECDE for infants and toddlers is 0.48 μg/kg bw per day, which represents 4.8% of the upper bound of the ADI of 10 μg/kg bw. (JECFA94)			
Residue Defi	nition	Ivermectin B _{1a} The marker residue in sheep, pigs and goats is ivermectin B _{1a} (H ₂ B _{1a} , or 22,23-dihydroavermectin B _{1a}). (JECFA94)			
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Cattle	Muscle	30	40 (2017)		
Cattle	Liver	800	40 (2017)		
Cattle	Kidney	100	40 (2017)		
Cattle	Fat	400	40 (2017)		
Cattle	Milk	10	26 (2003)		
Pig	Muscle	15	46 (2023)		
Pig	Liver	30	46 (2023)		
Pig	Kidney	20	46 (2023)		
Pig	Fat	50	46 (2023)		
Sheep and goats	Muscle	30 46 (2023)			
Sheep and goats	Liver	60	46 (2023)		
Sheep and goats	Kidney	20	46 (2023)		
Sheep and goats	Fat	100	46 (2023)		

LASALOCID	LASALOCID SODIUM (antiparasitic agent)					
JECFA Evalu	ıation	78 (2013)	78 (2013)			
Acceptable [Daily Intake	0-5 μg/kg bw on the basis of a NOAEL of 0.5 mg/kg bw per day from a developmental toxicity study in rabbits and a multigeneration reproductive toxicity study in rats, with application of an uncertainty factor of 100 for interspecies and intraspecies variability. (JECFA78)				
Estimated Di	etary Exposure			alculated, which represents approximately he ADI (JECFA78)		
Residue Defi	nition	Lasalocid A				
Note		JECFA78 extended the MRLs in chicken to turkey and quail and extrapolated the MRLs in chicken to pheasant. No information was available for duck, including on approved uses. As the compound is not registered for use in laying hens, according to the sponsor, it is not appropriate to recommend MRLs for egg.				
Species	Tissue	MRL (µg/kg)	CAC	Notes		
Chicken	Muscle	400	40 (2017)			
Chicken	Liver	1200	40 (2017)			
Chicken	Kidney	600	40 (2017)			
Chicken	Skin + Fat	600	40 (2017)			
Turkey	Muscle	400	40 (2017)			
Turkey	Liver	1200	40 (2017)			
Turkey	Kidney	600	40 (2017)			
Turkey	Skin + Fat	600	40 (2017)			
Quail	Muscle	400	40 (2017)			
Quail	Liver	1200	40 (2017)			
Quail	Kidney	600	40 (2017)			
Quail	Skin + Fat	600	40 (2017)			
Pheasant	Muscle	400	40 (2017)			
Pheasant	Liver	1200	40 (2017)			
Pheasant	Kidney	600	40 (2017)			
Pheasant	Skin + Fat	600	40 (2017)			

LEVAMISOLE (anthelmintic agent)						
JECFA Evalu	JECFA Evaluation		36 (1990); 42 (1994)			
Acceptable D	aily Intake	0-6 μg/kg bw (Ji	ECFA42)			
Residue Defi	nition	Levamisole				
Species	Tissue	MRL (µg/kg)	CAC	Notes		
Cattle	Muscle	10	22 (1997)			
Cattle	Liver	100	22 (1997)			
Cattle	Kidney	10	22 (1997)			
Cattle	Fat	10	22 (1997)			
Pig	Muscle	10	22 (1997)			
Pig	Liver	100	22 (1997)			
Pig	Kidney	10	22 (1997)			
Pig	Fat	10	22 (1997)			
Poultry	Muscle	10	22 (1997)			
Poultry	Liver	100	22 (1997)			
Poultry	Kidney	10	22 (1997)			
Poultry	Fat	10	22 (1997)			
Sheep	Muscle	10	22 (1997)			
Sheep	Liver	100	22 (1997)			
Sheep	Kidney	10	22 (1997)			
Sheep	Fat	10	22 (1997)			

LINCOMYCIN	LINCOMYCIN (antimicrobial agent)					
JECFA Evalu	JECFA Evaluation		54 (2000); 58 (2002); 62 (2004)			
Acceptable D	aily Intake	0-30 µg/kg bw	(JECFA54)			
Residue Defii	nition	Lincomycin				
Species	Tissue	MRL (μg/kg) CAC Notes				
Cattle	Milk	150	26 (2003)			
Chicken	Muscle	200	26 (2003)			
Chicken	Liver	500	26 (2003)			
Chicken	Kidney	500	26 (2003)			
Chicken	Fat	100	26 (2003)	Additional MRL for skin with adhering fat of 300 μg/kg		
Pig	Muscle	200	26 (2003)			
Pig	Liver	500	26 (2003)			
Pig	Kidney	1500	26 (2003)			
Pig	Fat	100	26 (2003)	Additional MRL for skin with adhering fat of 300 μg/kg		

LUFENURON	LUFENURON (insecticide)			
JECFA Evalua	ation	85 (2017)		
Acceptable Da	aily Intake	0–0.02 mg/kg bw based on the NOAEL of 1.93 mg/kg bw per day for tonic-clonic seizures and findings in lungs, gastrointestinal tract, liver and urinary tract in a 2-year dietary study in rats, and using a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability)		
Acute Referer	nce Dose	Unnecessary, in view of lufenuron low acute oral toxicity and the absence of developmental toxicity and other toxicological effects likely to be elicited by a single dose		
Estimated chronic dietary exposure		1.1 µg/kg bw per day (for the general population), which represents 5.5% of the upper bound of the ADI. As lufenuron is also used as pesticide, the overall dietary exposure was estimated. The assumptions and detailed results will be displayed in the JECFA85 report. Results below are only for use as veterinary drug.		
Residue Defin	ition	Lufenuron		
Species	Tissue	MRL (μg/kg) CAC Notes		
Salmon	Fillet	1350	41 (2018)	Muscle plus skin in natural proportion
Trout	Fillet	1350	41 (2018)	Muscle plus skin in natural proportion

MELENGESTROL ACETATE (production aid)					
JECFA Evalua	ation	54 (2000); 58 ((2002); 62 (20	004); 66 (2006) 70 (2008)	
Acceptable D	Acceptable Daily Intake		w (JECFA54)		
Residue Defir	nition	Melengestrol acetate			
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Cattle	Muscle	1	32 (2009)		
Cattle	Liver	10 32 (2009)			
Cattle	Kidney	2 32 (2009)			
Cattle	Fat	18	32 (2009)		

MONENSIN (antimicrobial agen	t)				
JECFA Evalu	uation	70 (2008); 75 (2011)				
Acceptable [Acceptable Daily Intake		0–10 μg/kg bw on the basis of a NOAEL of 1.14 mg/kg bw per day and a safety factor of 100 and rounding to one significant figure (JECFA70)			
Estimated Di	ietary Exposure		lue of 481 µg	MDI from JECFA70 was recalculated, /person, which represents 80% of the upper		
Residue Defi	inition	Monensin				
Species	Tissue	MRL (µg/kg)	CAC	Notes		
Cattle	Muscle	10	32 (2009)			
Cattle	Liver	100	35 (2012)			
Cattle	Kidney	10	32 (2009)			
Cattle	Fat	100	32 (2009)			
Cattle	Milk	2	32 (2009)			
Sheep	Muscle	10	32 (2009)			
Sheep	Liver	20	32 (2009)			
Sheep	Kidney	10	32 (2009)			
Sheep	Fat	100	32 (2009)			
Goats	Muscle	10	32 (2009)			
Goats	Liver	20	32 (2009)			
Goats	Kidney	10	32 (2009)			
Goats	Fat	100	32 (2009)			
Chicken	Muscle	10	32 (2009)			
Chicken	Liver	10	32 (2009)			
Chicken	Kidney	10	32 (2009)			
Chicken	Fat	100	32 (2009)			
Turkey	Muscle	10	32 (2009)			
Turkey	Liver	10	32 (2009)			
Turkey	Kidney	10	32 (2009)			
Turkey	Fat	100	32 (2009)			
Quail	Muscle	10	32 (2009)			
Quail	Liver	10	32 (2009)			
Quail	Kidney	10	32 (2009)			
Quail	Fat	100	32 (2009)			

MONEPANTE	MONEPANTEL (anthelmintic agent)					
JECFA Evalu	ation	75 (2011); 78 (2013), 85 (2017)				
Acceptable D	aily Intake	tonic-clonic se and urinary tra	0–0.02 mg/kg bw based on the NOAEL of 1.93 mg/kg bw per day for tonic-clonic seizures and findings in lungs, gastrointestinal tract, liver and urinary tract in a 2-year dietary study in rats, and using a safety factor of 100 (10 for interspecies variability and 10 for intraspecies variability)			
Acute Refere	nce Dose	Unnecessary				
Estimated Ch Exposure	ronic Dietary	 13.7 μg per kg bw per day (for the general population), which represent 68% of the upper bound of the ADI 5.0 μg per kg bw per day (for children), which represents 22% of the upper bound of the ADI 		the ADI		
		4.4 μg per kg bw per day (for infants), which represents 25% of the upper bound of the ADI				
Residue Defi	nition	Monepantel sulfone, expressed as monepantel				
Species	Tissue	MRL (µg/kg)	CAC	Notes		
Sheep	Muscle	500	38 (2015)			
Sheep	Liver	7000	38 (2015)			
Sheep	Kidney	1700	38 (2015)			
Sheep	Fat	13000 38 (2015)				
Fat		7000	41 (2018)			
Cattle	Kidney		41 (2018)			
Callle	Liver	2000	41 (2018)			
	Muscle	300	41 (2018)			

MOXIDECTIN (anthelmintic agent)						
JECFA Evaluation Acceptable Daily Intake Residue Definition		45 (1995); 47 (1996); 48 (1998); 50 (1998)				
		0-2 μg/kg bw (JECFA45) Moxidectin				
Cattle	Muscle	20	22 (1997)	Very high concentration and great variation in the level of residues at the injection site in cattle over a 49-day period after dosing		
Cattle	Liver	100	22 (1997)			
Cattle	Kidney	50	22 (1997)			
Cattle	Fat	500	22 (1997)			
Deer	Muscle	20	23 (1999)			
Deer	Liver	100	23 (1999)			
Deer	Kidney	50	23 (1999)			
Deer	Fat	500	23 (1999)			
Sheep	Muscle	50	22 (1997)			
Sheep	Liver	100	22 (1997)			
Sheep	Kidney	50	22 (1997)			
Sheep	Fat	500	22 (1997)			

NARASIN (antimicrobial agent)						
JECFA Evaluation		70 (2008); 75 (2011)				
Acceptable Daily Intake		0-5 μg/kg bw on the basis of a NOAEL of 0.5 mg/kg bw per day and a safety factor of 100 (JECFA70)				
Residue Definition		Narasin A				
Species	Tissue	MRL (µg/kg)	CAC	Notes		
Cattle	Muscle	15	35 (2012)			
Cattle	Liver	50	35 (2012)			
Cattle	Kidney	15	35 (2012)			
Cattle	Fat	50	35 (2012)			
Chicken	Muscle	15	32 (2009)			
Chicken	Liver	50	32 (2009)			
Chicken	Kidney	15	32 (2009)			
Chicken	Fat	50	32 (2009)			
Pig	Muscle	15	34 (2011)			
Pig	Liver	50	34 (2011)			
Pig	Kidney	15	34 (2011)			
Pig	Fat	50	34 (2011)			

NEOMYCIN (antimicrobial age	nt)					
JECFA Evaluation		43 (1994); 47	43 (1994); 47 (1996); 52 (1999); 58 (2002); 60 (2003)				
Acceptable Daily Intake		0-60 μg/kg bw (JECFA47)					
Residue Definition		Neomycin					
Species	Tissue	MRL (µg/kg)	CAC	Notes			
Cattle	Muscle	500	23 (1999)				
Cattle	Liver	500	28 (2005)				
Cattle	Kidney	10000	28 (2005)				
Cattle	Fat	500	23 (1999)				
Cattle	Milk	1500	28 (2005)				
Chicken	Muscle	500	23 (1999)				
Chicken	Liver	500	23 (1999)				
Chicken	Kidney	10000	23 (1999)				
Chicken	Fat	500	23 (1999)				
Chicken	Eggs	500	23 (1999)				
Duck	Muscle	500	23 (1999)				
Duck	Liver	500	23 (1999)				
Duck	Kidney	10000	23 (1999)				
Duck	Fat	500	23 (1999)				
Goat	Muscle	500	23 (1999)				
Goat	Liver	500	23 (1999)				
Goat	Kidney	10000	23 (1999)				
Goat	Fat	500	23 (1999)				
Pig	Muscle	500	23 (1999)				
Pig	Liver	500	23 (1999)				
Pig	Kidney	10000	23 (1999)				
Pig	Fat	500	23 (1999)				
Sheep	Muscle	500	23 (1999)				
Sheep	Liver	500	23 (1999)				
Sheep	Kidney	10000	23 (1999)				
Sheep	Fat	500	23 (1999)				
Turkey	Muscle	500	23 (1999)				
Turkey	Liver	500	23 (1999)				
Turkey	Kidney	10000	23 (1999)				
Turkey	Fat	500	23 (1999)				

NICARBAZIN (coccidiostat)					
JECFA Evalu	,	50 (1998), 94 (2	021)		
Acceptable D	Paily Intake	0–0.9mg/kg bw	based on tox	icological effects (JECFA94)	
Acute Refere	nce Dose	Not necessary (JECFA94)		
Estimated Ch Exposure	ronic Dietary			lues in chicken muscle, offal, and skin with ne and 125 mg/kg feed:	
				ne elderly is 120 µg/kg body weight (bw) per f the upper bound of the ADI of	
				adolescents is 160 μg/kg bw per day, upper bound of the ADI of 900 μg/kg bw.	
		represents 23%	of the upper	oddlers is 210 µg/kg bw per day, which bound of the ADI of 900 µg/kg bw.	
				lues in chicken muscle, offal, and hdrawal time and 50 mg/kg feed:	
				ne elderly is 95 μg/kg bw per day, which bound of the ADI of 900 μg/kg bw.	
				adolescents is 120 μg/kg bw per day, upper bound of the ADI of 900 μg/kg bw.	
				oddlers is 160 µg/kg bw per day, which bound of the ADI of 900 µg/kg bw.	
		(JECFA94)	от што аррот	zeant or the right of each parties at the	
Microbiologic	cal effects	Nicarbazin and/or its metabolites show no antimicrobial activity towards representative bacteria of the human intestinal microbiota.			
Microbiologic	cal ADI	JECFA concluded that it was not necessary to establish an mADI for nicarbazin.			
Toxicologica	l effects	The NOAEL was 60 mg/kg bw per day (equivalent to 42.5 mg/kg bw per day of DNC) due to prominent liver lobulation, observed in a study of developmental toxicity in the rabbit.			
Uncertainty factor		When considering nicarbazin it is DNC that is the toxic component, and its absorption alone or in a mixture with HDP is substantially less (< 5%) than when formed from ingested nicarbazin. As DNC is the residue of concern and there is no nicarbazin in products from treated animals, JECFA concluded that despite limitations in the database, a reduction in the default safety factor of 100 used to account for interspecies and intraspecies variability, would be justified. JECFA was unable to quantify just how much of a reduction would be appropriate, but concluded that 50 could certainly be supported, and would still result in a conservative evaluation.			
Toxicological Acceptable Daily Intake		The tADI for nicarbazin was established at 0–0.9 mg/kg bw (DNC).			
Residue Definition		The marker resid	due in chicke	ns is 4,4'-dinitrocarbanilide (DNC) DNC.	
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Chicken	Muscle	4000	23 (1999)	Broilers	
Chicken	Liver	15000	23 (1999)	Broilers	
Chicken	Kidney	8000	23 (1999)	Broilers	
Chicken	Fat/Skin (skin with fat)	4000	23 (1999)	Broilers	

PHOXIM (inse	PHOXIM (insecticide)						
JECFA Evaluation		52 (1999); 62 (52 (1999); 62 (2004)				
Acceptable [Daily Intake	0-4 μg/kg bw (JECFA52)				
Residue Defi	inition	Phoxim					
Species	Tissue	MRL (µg/kg)	I (A () NOTAS				
Goat	Muscle	50	26 (2003)				
Goat	Liver	50	26 (2003)				
Goat	Kidney	50	26 (2003)				
Goat	Fat	400	26 (2003)				
Pig	Muscle	50	26 (2003)				
Pig	Liver	50	26 (2003)				
Pig	Kidney	50	26 (2003)				
Pig	Fat	400	26 (2003)				
Sheep	Muscle	50	26 (2003)				
Sheep	Liver	50	26 (2003)				
Sheep	Kidney	50	26 (2003)				
Sheep	Fat	400	26 (2003)				

PIRLIMYCIN (PIRLIMYCIN (antimicrobial agent)				
JECFA Evaluation		62 (2004)			
Acceptable Da	aily Intake	0-8 μg/kg bw (JE	CFA62)		
Residue Defin	nition	Pirlimycin			
Species	Tissue	MRL (µg/kg)	CAC	Note	
Cattle	Muscle	100	29 (2006)		
Cattle	Liver	1000	29 (2006)		
Cattle	Kidney	400	29 (2006)		
Cattle	Fat	100	29 (2006)		
Cattle	Milk	100	29 (2006)	JECFA evaluated the effect of pirlimycin residues on starter cultures and for this reason recommended an MRL of 100 µg/kg of milk. Codex Members may therefore adapt national/regional MRLs in order to address this technological aspect for trade of fresh liquid milk intended for processing using starter culture.	

PORCINE SOMATOTROPIN (production aid)				
JECFA Evalua	ation	52 (1999)		
Acceptable D	reptable Daily Intake Not Specified (JECFA52)			
Residue Defir	nition	Not applicable		
Species	Tissue	MRL (μg/kg) CAC Notes		
Pig	Muscle	not specified	26 (2003)	
Pig	Liver	not specified 26 (2003)		
Pig	Kidney	not specified 26 (2003)		
Pig	Fat	not specified	26 (2003)	

PROGESTER	PROGESTERONE (production aid)						
JECFA Evaluation		25 (1981); 32 (25 (1981); 32 (1987); 52 (1999)				
Acceptable D	aily Intake	0-30 µg/kg bw	(JECFA52)				
Residue Defi	nition	Progesterone					
Species	Tissue	MRL (µg/kg)	CAC	Notes			
Cattle	Muscle	unnecessary	21 (2005)	Residues resulting from the use of this substances as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health			
Cattle	Liver	unnecessary	21 (2005)	Residues resulting from the use of this substances as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health			
Cattle	Kidney	unnecessary	21 (2005)	Residues resulting from the use of this substances as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health			
Cattle	Fat	unnecessary	21 (2005)	Residues resulting from the use of this substances as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health			

RACTOPAMINE (production aid)							
JECFA Evalu	ation	40 (1992); 62 (40 (1992); 62 (2004); 66 (2006)				
Acceptable D	aily Intake	0-1 μg/kg bw (JECFA66)				
Residue Defi	nition	Ractopamine					
Species	Tissue	MRL (µg/kg)	I CAC Notas				
Cattle	Muscle	10	35 (2012)				
Cattle	Liver	40	35 (2012)				
Cattle	Kidney	90	35 (2012)				
Cattle	Fat	10	35 (2012)				
Pig	Muscle	10	35 (2012)				
Pig	Liver	40	35 (2012)				
Pig	Kidney	90	35 (2012)				
Pig	Fat	10	35 (2012)	The MRL includes skin + fat			

SARAFLOXACIN (antimicrobial agent)				
JECFA Evaluation	on	50 (1998)		
Acceptable Dail	y Intake	0-0.3 μg/kg bw	(JECFA50)	
Residue Definiti	on	Sarafloxacin		
Species	Tissue	MRL (µg/kg)	CAC	Notes
Chicken	Muscle	10	24 (2001)	
Chicken	Liver	80	24 (2001)	
Chicken	Kidney	80	24 (2001)	
Chicken	Fat	20	24 (2001)	
Turkey	Muscle	10	24 (2001)	
Turkey	Liver	80	24 (2001)	
Turkey	Kidney	80	24 (2001)	
Turkey	Fat	20	24 (2001)	

SPECTINOMYCIN (antimicrobial agent)						
JECFA Evalua	ation	42 (1994); 50 (42 (1994); 50 (1998)			
Acceptable D	aily Intake	0-40 μg/kg bw	(JECFA42)			
Residue Defir	nition	Spectinomycin				
Species	Tissue	MRL (µg/kg)	CAC	Notes		
Cattle	Muscle	500	23 (1999)			
Cattle	Liver	2000	23 (1999)			
Cattle	Kidney	5000	23 (1999)			
Cattle	Fat	2000	23 (1999)			
Cattle	Milk (µg/I)	200	23 (1999)			
Chicken	Muscle	500	23 (1999)			
Chicken	Liver	2000	23 (1999)			
Chicken	Kidney	5000	23 (1999)			
Chicken	Fat	2000	23 (1999)			
Chicken	Eggs	2000	23 (1999)			
Pig	Muscle	500	23 (1999)			
Pig	Liver	2000	23 (1999)			
Pig	Kidney	5000	23 (1999)			
Pig	Fat	2000	23 (1999)			
Sheep	Muscle	500	23 (1999)			
Sheep	Liver	2000	23 (1999)			
Sheep	Kidney	5000	23 (1999)			
Sheep	Fat	2000	23 (1999)			

SPIRAMYCIN	(antimicrobial age	ent)					
JECFA Evaluation		38 (1991); 43 (38 (1991); 43 (1994); 47 (1996); 48 (1997)				
Acceptable D	Daily Intake	0-50 μg/kg bw	(JECFA43)				
Residue Defi	nition			f spiramycin and neospiramycin; s (antimicrobially active residues)			
Species	Tissue	MRL (µg/kg)	CAC	Notes			
Cattle	Muscle	200	22 (1997)				
Cattle	Liver	600	22 (1997)				
Cattle	Kidney	300	22 (1997)				
Cattle	Fat	300	22 (1997)				
Cattle	Milk (µg/l)	200	22 (1997)				
Chicken	Muscle	200	22 (1997)				
Chicken	Liver	600	22 (1997)				
Chicken	Kidney	800	22 (1997)				
Chicken	Fat	300	22 (1997)				
Pig	Muscle	200	22 (1997)				
Pig	Liver	600	22 (1997)				
Pig	Kidney	300	22 (1997)				
Pig	Fat	300	22 (1997)				

SULFADIMIDINE (antimicrobial agent)					
JECFA Evalua	ation	34 (1989); 38 ((1991); 42 (19	994)	
Acceptable Da	aily Intake	0-50 μg/kg bw	(JECFA42)		
Residue Defir	nition	Sulfadimidine			
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Cattle	Milk (µg/l)	25	21 (1995)		
Not specified	Muscle	100	21 (1995)		
Not specified	Liver	100	21 (1995)		
Not specified	Kidney	100 21 (1995)			
Not specified	Fat	100	21 (1995)		

TEFLUBENZU	TEFLUBENZURON (insecticide)				
JECFA Evalua	ation	81 (2015)			
Acceptable Daily Intake 0-5 μg/kg bw on the basis of a lower 95% confide benchmark dose for a 10% response (BMDL10) of bw per day for hepatocellular hypertrophy in male observed in a carcinogenicity study, with application uncertainty factor of 100 to account for interspecies intraspecies variability. (JECFA81)			response (BMDL10) of 0.54 mg/kg ar hypertrophy in male mice ty study, with application of an account for interspecies and		
Estimated chronic dietary exposure		The EDI is 42.9 µg/person per day, on the basis of a 60 kg individual, which represents approximately 14% of the upper bound of the ADI. The GECDE for the general population is 1.6 µg/kg bw per day, which represents 31% of the upper bound of the ADI. The GECDE for children is 2.1 µg/kg bw per day, which represents 43% of the upper bound of the ADI. The GECDE for infants is 0.9 µg/kg bw per day, which represents 18% of the upper bound of the ADI. (JECFA81)			
Residue Defir	nition	Teflubenzuron			
Species	Tissue	MRL (μg/kg) CAC Notes			
Salmon	Muscle	400	40 (2017)		
Salmon	Fillet	400	40 (2017)	Muscle plus skin in natural proportion	

TESTOSTERONE (production aid)						
JECFA Evalu	uation	25 (1981); 32 (25 (1981); 32 (1987); 52 (1999)			
Acceptable [Daily Intake	0-2 μg/kg bw (JECFA52)			
Residue Defi	inition	Testosterone				
Species	Tissue	MRL (µg/kg) CAC Notes				
Cattle	Muscle	unnecessary	21 (1995)	Residues resulting from the use of this substances as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health.		
Cattle	Liver	unnecessary	21 (1995)	Residues resulting from the use of this substances as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health.		
Cattle	Kidney	unnecessary	21 (1995)	Residues resulting from the use of this substances as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health.		
Cattle	Fat	unnecessary	21 (1995)	Residues resulting from the use of this substances as a growth promoter in accordance with good animal husbandry practice are unlikely to pose a hazard to human health.		

THIABENDAZOLE (anthelmintic agent)							
JECFA Evalu	ıation	40 (1992); 48 (1997); 58 (2002)					
Acceptable [Daily Intake	0-100 μg/kg b	0-100 μg/kg bw (JECFA40)				
Residue Defi	Residue Definition		Sum of thiabendazole and 5-hydroxythiabendazole				
Species	Tissue	MRL (µg/kg)	(:Δ(: Νοτος				
Cattle	Muscle	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Cattle	Liver	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Cattle	Kidney	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Cattle	Fat	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Cattle	Milk (µg/l)	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Goat	Muscle	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Goat	Liver	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Goat	Kidney	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Goat	Fat	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Goat	Milk (µg/l)	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Pig	Muscle	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Pig	Liver	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Pig	Kidney	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use.			
Pig	Fat	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			
Sheep	Muscle	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use			

Species	Tissue	MRL (µg/kg)	CAC	Notes
Sheep	Liver	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use
Sheep	Kidney	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use
Sheep	Fat	100	21 (1995)	The MRL also covers residues derived from feed containing the residues resulted from agricultural use

TILMICOSIN (TILMICOSIN (antimicrobial agent)				
JECFA Evalua	ation	47 (1996); 54 (2000); 70 (20		008)	
Acceptable D	aily Intake	0-40 µg/kg bw	(JECFA47)		
Residue Defir	nition	Tilmicosin			
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Cattle	Muscle	100	23 (1999)		
Cattle	Liver	1000	23 (1999)		
Cattle	Kidney	300	23 (1999)		
Cattle	Fat	100	23 (1999)		
Chicken	Muscle	150	34 (2011)		
Chicken	Liver	2400	34 (2011)		
Chicken	Kidney	600	34 (2011)		
Chicken	Skin/Fat	250	34 (2011)		
Pig	Muscle	100	23 (1999)		
Pig	Liver	1500	23 (1999)		
Pig	Kidney	1000	23 (1999)		
Pig	Fat	100	23 (1999)		
Sheep	Muscle	100	23 (1999)		
Sheep	Liver	1000	23 (1999)		
Sheep	Kidney	300	23 (1999)		
Sheep	Fat	100	23 (1999)		
Turkey	Muscle	100	34 (2011)		
Turkey	Kidney	1200	34 (2011)		
Turkey	Liver	1400	34 (2011)		
Turkey	Skin/Fat	250	34 (2011)		

TRENBOLON	TRENBOLONE ACETATE (growth promoter)				
JECFA Evalu	ation	26 (1982); 27 (1983); 32 (19	987); 34 (1989)	
Acceptable D	aily Intake	0-0.02 μg/kg b	w (JECFA34))	
Residue Defir	nition	Cattle muscle, beta-Trenbolone; Cattle liver, alpha-Trenbolone			
Species	Tissue	MRL (μg/kg) CAC Notes			
Cattle	Muscle	2 21 (1995)			
Cattle	Liver	10	21 (1995)		

TRICHLORFO	TRICHLORFON (Metrifonate) (insecticide)				
JECFA Evalua	ntion	54 (2000); 60 (2	2003); 66 (20	06)	
Acceptable Da	aily Intake	0-2 μg/kg bw (J	IECFA60)		
Residue Definition		JECFA54 confirmed the MRL for cows' milk and the guidance levels for muscle, liver, kidney, and fat of cattle recommended (WHO TRS 900, 2001)			
Species	Tissue	MRL (µg/kg) CAC Notes		Notes	
Cattle	Milk	50	29 (2006)		

TRICLABENDAZOLE (anthelmintic agent)					
JECFA Evalu	ation	40 (1992); 66 ((2006); 70 (20	008)	
Acceptable D	aily Intake	0-3 μg/kg bw (JECFA40)		
Residue Defi	nition	Ketotriclabned	azole		
Species	Tissue	MRL (µg/kg)	CAC	Notes	
Cattle	Muscle	250	32 (2009)		
Cattle	Liver	850	32 (2009)		
Cattle	Kidney	400	32 (2009)		
Cattle	Fat	100	32 (2009)		
Sheep	Muscle	200	32 (2009)		
Sheep	Liver	300 32 (2009)			
Sheep	Kidney	200 32 (2009)			
Sheep	Fat	100	32 (2009)		

TYLOSIN (an	timicrobial agent)						
JECFA Evaluation		70 (2008)	70 (2008)				
Acceptable [Daily Intake		0-30 μg/kg bw based on a microbiological end-point derived from in vitro MIC susceptibility testing and faecal binding data (MICcalc = 1.698) (JECFA70)				
Residue Defi	inition	Tylosin A					
Species	Tissue	MRL (µg/kg)	CAC	Notes			
Cattle	Muscle	100	32 (2009)				
Cattle	Liver	100	32 (2009)				
Cattle	Kidney	100	32 (2009)				
Cattle	Fat	100	32 (2009)				
Cattle	Milk	100	32 (2009)				
Pig	Muscle	100	32 (2009)				
Pig	Liver	100	32 (2009)				
Pig	Kidney	100	32 (2009)				
Pig	Fat	100	32 (2009)				
Chicken	Muscle	100	32 (2009)				
Chicken	Liver	100	32 (2009)				
Chicken	Kidney	100	32 (2009)				
Chicken	Fat/Skin	100	32 (2009)				
Chicken	Eggs	300	32 (2009)				

ZERANOL (growth promoter)					
JECFA Evalu	ation	26 (1982); 27 (1983); 32 (1987)			
Acceptable D	aily Intake	0-0.5 μg/kg bw	(JECFA32)		
Residue Defir	nition	Zeranol			
Species	Tissue	MRL (μg/kg) CAC Notes			
Cattle	Muscle	2 21 (1995)			
Cattle	Liver	10	21 (1995)		

ZILPATEROL HYDROCHLO		(β2-adrenoceptor agonist)				
JECFA Evalu	ations	81 (2015), 85 ((2017)			
Acceptable [Daily Intake			blished at JECFA78 and reaffirmed at JECFA81 and JECFA85.		
Acute Refere	ence Dose	ARfD is 0.04 µg/kg bw based on a lowest-observed-adverse-effect level (LOAEL) of 0.76 µg/kg bw for acute pharmacological effects observed in a single-dose human study, with application of an uncertainty factor of 20, comprising a default uncertainty factor of 10 for human individual variability and an additional uncertainty factor of 2 to account for use of a LOAEL for a slight effect instead of a NOAEL (JECFA81).				
Global Estim		approximately The GEADE is	80% of the A 0.57 μg/day	e general population, which represents RfD. for children, which represents RfD (JECFA81).		
Residue Defi	nition	Zilpaterol (free	Zilpaterol (free base) in muscle, liver, and kidney.			
Species	Tissue	MRL (μg/kg) CAC Notes				
Cattle	Kidney	3.3	3.3 46 (2023)			
Cattle	Liver	3.5	3.5 46 (2023)			
Cattle	Muscle	0.5	46 (2023)			

PART II

MAXIMUM RESIDUE LIMITS FOR RESIDUES OF VETERINARY DRUGS IN FOODS EXTRAPOLATED IN ACCORDANCE WITH THE APPROACH FOR THE EXTRAPOLATION OF MRLs FOR VETERINARY DRUGS TO ONE OR MORE SPECIES

Extrapolation to ruminants

AMOXICILLIN

Species	Tissue	MRL (µg/kg)	Note
All other ruminants	Muscle	50	MRL extrapolated
All other ruminants	Fat	50	MRL extrapolated
All other ruminants	Liver	50	MRL extrapolated
All other ruminants	Kidney	50	MRL extrapolated
All other ruminants	Milk	4	MRL extrapolated

BENZYLPENICILLIN

Species	Tissue	MRL (µg/kg)	Note
All other ruminants	Muscle	50	MRL extrapolated
All other ruminants	Liver	50	MRL extrapolated
All other ruminants	Kidney	50	MRL extrapolated
All other ruminants	Milk	4	MRL extrapolated

CYHALOTHRIN

Species	Tissue	MRL (µg/kg)	Note
All other ruminants	Muscle	20	MRL extrapolated
All other ruminants	Fat	400	MRL extrapolated
All other ruminants	Liver	20	MRL extrapolated
All other ruminants	Kidney	20	MRL extrapolated
All other ruminants	Milk	30	MRL extrapolated

CYPERMETHRIN

Species	Tissue	MRL (µg/kg)	Note
All other ruminants	Muscle	50	MRL extrapolated
All other ruminants	Fat	1000	MRL extrapolated
All other ruminants	Liver	50	MRL extrapolated
All other ruminants	Kidney	50	MRL extrapolated

DELTAMETHRIN

Species	Tissue	MRL (µg/kg)	Note
All other ruminants	Muscle	30	MRL extrapolated
All other ruminants	Fat	500	MRL extrapolated
All other ruminants	Liver	50	MRL extrapolated
All other ruminants	Kidney	50	MRL extrapolated

LEVAMISOLE

Species	Tissue	MRL (µg/kg)	Note
All other ruminants	Muscle	10	MRL extrapolated
All other ruminants	Fat	10	MRL extrapolated
All other ruminants	Liver	100	MRL extrapolated
All other ruminants	Kidney	10	MRL extrapolated

MOXIDECTIN

Species	Tissue	MRL (µg/kg)	Note
All other ruminants	Muscle	20	MRL extrapolated
All other ruminants	Fat	500	MRL extrapolated
All other ruminants	Liver	100	MRL extrapolated
All other ruminants	Kidney	50	MRL extrapolated

SPECTINOMYCIN

Species	Tissue	MRL (µg/kg)	Note
All other ruminants	Muscle	500	MRL extrapolated
All other ruminants	Fat	2000	MRL extrapolated
All other ruminants	Liver	2000	MRL extrapolated
All other ruminants	Kidney	5000	MRL extrapolated
All other ruminants	Milk	200	MRL extrapolated

TETRACYCLINES

Species	Tissue	MRL (µg/kg)	Note
All other ruminants	Muscle	200	MRL extrapolated
All other ruminants	Liver	600	MRL extrapolated
All other ruminants	Kidney	1200	MRL extrapolated
All other ruminants	Milk	100	MRL extrapolated

TILMICOSIN

Species	Tissue	MRL (µg/kg)	Note
All other ruminants	Muscle	100	MRL extrapolated
All other ruminants	Fat	100	MRL extrapolated
All other ruminants	Liver	1000	MRL extrapolated
All other ruminants	Kidney	300	MRL extrapolated

Extrapolation to finfish

DELTAMETHRIN

Species	Tissue	MRL (µg/kg)	Note
All other finfish	Muscle	30	MRL extrapolated

FLUMEQUINE

Species	Tissue	MRL (µg/kg)	Note
All other finfish	Muscle	500	MRL extrapolated

PART III

RISK MANAGEMENT RECOMMENDATIONS (RMRs) FOR RESIDUES OF VETERINARY DRUGS

CARBADOX (growth promoter)

JECFA evaluation: 36 (1990); 60 (2003)

CAC adoption: 37 (2014)

Recommended risk management measures

In view of the JECFA conclusions on the available scientific information, there is no safe level of residues of carbadox or its metabolites in food that represents an acceptable risk to consumers. For this reason, competent authorities should prevent residues of carbadox in food. This can be accomplished by not using carbadox in food producing animals.

CHLORAMPHENICOL (antimicrobial agent)

JECFA evaluation: 12 (1968); 32 (1987); 42 (1994); 62 (2004)

CAC adoption: 37 (2014)

Recommended risk management measures

In view of the JECFA conclusions on the available scientific information, there is no safe level of residues of chloramphenicol or its metabolites in food that represents an acceptable risk to consumers. For this reason, competent authorities should prevent residues of chloramphenicol in food. This can be accomplished by not using chloramphenicol in food producing animals.

CHLORPROMAZINE (tranquilliser agent)

JECFA evaluation: 38 (1991) **CAC adoption:** 37 (2014)

Recommended risk management measures

In view of the JECFA conclusions, although insufficient data were available or there was a lack of data to establish a safe level of residues of chlorpromazine or its metabolites in food representing an acceptable risk to consumers, significant health concerns were identified. For this reason, competent authorities should prevent residues of chlorpromazine in food. This can be accomplished by not using chlorpromazine in food producing animals.

DIMETRIDAZOLE (antiprotozoal agent)

JECFA evaluation: 34 (1989) **CAC adoption:** 38 (2015)

Recommended risk management measures

In view of the JECFA conclusions, although insufficient data were available or there was a lack of data to establish a safe level of residues of dimetridazole or its metabolites in food representing an acceptable risk to consumers, significant health concerns were identified. For this reason, competent authorities should prevent residues of dimetridazole in food. This can be accomplished by not using dimetridazole in food producing animals.

FURAZOLIDONE (antimicrobial agent)

JECFA evaluation: 40 (1992) **CAC adoption:** 37 (2014)

Recommended risk management measures

In view of the JECFA conclusions on the available scientific information, there is no safe level of residues of furazolidone or its metabolites in food that represents an acceptable risk to consumers. For this reason, competent authorities should prevent residues of furazolidone in food. This can be accomplished by not using furazolidone in food producing animals.

GENTIAN VIOLET (antibacterial, antifungal and anthelminthic agent)

JECFA evaluation: 78 (2013) **CAC adoption:** 41 (2018)

Recommended risk management measures

In view of the JECFA conclusions on the available scientific information, there is no safe level of residues of gentian violet or its metabolites in food that represents an acceptable risk to consumers. For this reason, competent authorities should prevent residues of gentian violet in food. This can be accomplished by not using gentian violet in food producing animals.

IPRONIDAZOLE (antiprotozoal agent)

JECFA evaluation: 34 (1989) **CAC adoption:** 38 (2015)

Recommended risk management measures

In view of the JECFA conclusions, although insufficient data were available or there was a lack of data to establish a safe level of residues of ipronidazole or its metabolites in food representing an acceptable risk to consumers, significant health concerns were identified. For this reason, competent authorities should prevent residues of ipronidazole in food. This can be accomplished by not using ipronidazole in food producing animals.

MALACHITE GREEN (antifungal and antiprotozoal agent)

JECFA evaluation: 70 (2008) CAC adoption: 37 (2014)

Recommended risk management measures

In view of the JECFA conclusions on the available scientific information, there is no safe level of residues of malachite green or its metabolites in food that represents an acceptable risk to consumers. For this reason, competent authorities should prevent residues of malachite green in food. This can be accomplished by not using malachite green in food producing animals.

METRONIDAZOLE (antiprotozoal agent)

JECFA evaluation: 34 (1989) **CAC adoption:** 38 (2015)

Recommended risk management measures

In view of the JECFA conclusions, although insufficient data were available or there was a lack of data to establish a safe level of residues of metronidazole or its metabolites in food representing an acceptable risk to consumers, significant health concerns were identified. For this reason, competent authorities should prevent residues of metronidazole in food. This can be accomplished by not using metronidazole in food producing animals.

NITROFURAL (antimicrobial agent)
JECFA evaluation: 40 (1992)
CAC adoption: 37 (2014)

Recommended risk management measures

In view of the JECFA conclusions, although insufficient data were available or there was a lack of data to establish a safe level of residues of nitrofural or its metabolites¹ in food representing an acceptable risk to consumers, significant health concerns were identified. For this reason, competent authorities should prevent residues of nitrofural in food. This can be accomplished by not using nitrofural in food producing animals.

¹ Semicarbazide is not a unique indicator of nitrofural use and low levels can be associated with other legitimate sources.

OLAQUINDOX (antibacterial agent) **JECFA evaluation:** 36 (1990); 42 (1994)

CAC adoption: 37 (2014)

Recommended risk management measures

In view of the JECFA conclusions, although insufficient data were available or there was a lack of data to establish a safe level of residues of olaquindox or its metabolites in food representing an acceptable risk to consumers, significant health concerns were identified. For this reason, competent authorities should prevent residues of olaquindox in food. This can be accomplished by not using olaquindox in food producing animals.

RONIDAZOLE (antiprotozoal agent)

JECFA evaluation: 34 (1989); 42 (1994)

CAC adoption: 38 (2015)

Recommended risk management measures

In view of the JECFA conclusions, although insufficient data were available or there was a lack of data to establish a safe level of residues of ronidazole or its metabolites in food representing an acceptable risk to consumers, significant health concerns were identified. For this reason, competent authorities should prevent residues of ronidazole in food. This can be accomplished by not using ronidazole in food producing animals.

STILBENES (growth promoter) **JECFA evaluation:** 5 (1960)

IARC evaluation: monograph 100A (2012)

CAC adoption: 37 (2014)

Recommended risk management measures

In view of the available scientific information, there is no safe level of residues of stilbenes or their metabolites in food that represents an acceptable risk to consumers. For this reason, competent authorities should prevent residues of stilbenes in food. This can be accomplished by not using stilbenes in food producing animals.